

1 Title: **Evaluation of Risk Factors associated with SARS-CoV-2 Transmission**

2
3 Running title: **Risk factors of SARS-CoV-2 transmission**

4
5 Mai Ngoc Luu^{a,†}, Shamael Thabit Mohammed Alhady^{b,†}, Nguyen Tran Minh Duc^{c,†}, Le Van
6 Truong^{d,†}, Ahmad Qarawi^e, U Venkatesh^f, Ranjit Tiwari^g, Ian Christopher Naungayan Rocha^h, Le
7 Huu Nhat Minhⁱ, Rohanti Ravikulan^j, Shyam Prakash Dumre^k, Hoang Thi Nam Giang^l, Dmytro
8 Pavlenko^m, Fatmaelzahraa Yasser Aliⁿ, Bao-Tran Do Le^o, Sedighe Karimzadeh^p, Parshal
9 Bhandari^q, Jaffer Shah^r, Jeza Muhamad Abdul Aziz^{s,t}, Nguyen Tien Huy^{u,*}, and the TMGH
10 COVID-19 Collaborators[‡]

11
12 ^aDepartment of Internal Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho
13 Chi Minh City, Vietnam

14 ^bFaculty of Medicine, University of Gezira, Wad Medani, Sudan

15 ^cFaculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh
16 City, Vietnam

17 ^dTraditional Medicine Hospital, Ministry of the Public Security, Hanoi, Vietnam

18 ^eEssen Healthcare, Bronx, NY, United States

19 ^fDepartment of Community Medicine & Family Medicine, All India Institute of Medical Sciences,
20 Gorakhpur, India

21 ^gB.P. Koirala Institute of Health Sciences, Dharan, Nepal

22 ^hSchool of Medicine, Centro Escolar University, Manila, Philippines

23 ⁱMethodist Hospital, Merrillville, Indiana, United States

24 ^jFlinders Medical Centre, Bedford Park, South Australia, Australia

25 ^kCentral Department of Microbiology, Tribhuvan University, Kathmandu, Nepal

26 ^lDa Nang University, Da Nang, Vietnam

27 ^mDepartment of Ophthalmology, Bogomolets National Medical University, Kyiv, Ukraine

28 ⁿFaculty of Medicine, Zagazig University, Zagazig, Egypt

29 ^oFaculty of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA
30 90095-1569, United States

31 ^pOnline Research Club, Nagasaki University, Nagasaki, Japan

1 ^qDepartment of Anesthesia and Intensive Care, PGMI/Lahore General Hospital, Lahore, Pakistan

2 ^rMedical Research Center, Kateb University, Kabul, Afghanistan. Drexel University College of
3 Medicine, Philadelphia, Pennsylvania, USA

4 ^s Baxshin research center, Baxshin Hospital, Sulaymaniyah, Kurdistan Region, Iraq

5 ^t Medical Laboratory Science, College of Health Sciences, University of Human Development,
6 Sulaymaniyah, Kurdistan Region, Iraq

7 ^uSchool of Tropical Medicine and Global Health, Nagasaki University 1-12-4 Sakamoto,
8 Nagasaki, 852-8523, Japan

9 [†]Mai Ngoc Luu, Shamael Thabit Mohammed Alhady, Nguyen Tran Minh Duc and Le Van Truong
10 contributed equally to this work.

11 ***Correspondence:** Nguyen Tien Huy, School of Tropical Medicine and Global Health, Nagasaki
12 University 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan (E-mail: tienhuy@nagasaki-u.ac.jp;
13 Phone number: 81-95-819-7558)

14 ‡ For the list of Collaborators see Supplementary file S1

15 The authors wish it to be known that, in their opinion, the first 4 authors should be regarded as
16 joint First Authors.

17

18 **Email and ORCID**

19 Mai Ngoc Luu: ngmai3288@gmail.com; 0000-0002-8129-1764

20 Shamael Thabit Mohammed Alhady: shamaelthabit4321@gmail.com; 0000-0001-7463-3300

21 Nguyen Tran Minh Duc: minhduc1298@gmail.com; 0000-0002-9333-7539

22 Le Van Truong: bs.vantruong@gmail.com; 0000-0002-7474-0453

23 Ahmad Qarawi: aqarawi@essenmed.com; 0000-0001-7278-9889

24 U Venkatesh: venkatesh2007mbbs@gmail.com; 0000-0001-8059-9364

25 Ranjit Tiwari: docranjittiwari@gmail.com; 0000-0002-2148-4839

26 Ian Christopher Naungayan Rocha: rocha1750018@ceu.edu.ph; 0000-0002-8775-6876

27 Le Huu Nhat Minh: lehuunhatminh.md@ump.edu.vn; 0000-0002-7728-1539

28 Rohanti Ravikulan: r.rohanti@gmail.com; 0000-0002-6402-127

29 Shyam Prakash Dumre: sp.dumre@gmail.com; 0000-0002-4072-0745

30 Hoang Thi Nam Giang: htngiang@ud.edu.vn; 0000-0002-8648-483X

31 Dmytro Pavlenko: pavlenkomd@gmail.com; 0000-0001-8761-9559

- 1 Fatmaelzahraa Yasser Ali: fatmaelzahraa142@gmail.com
- 2 Bao-Tran Do Le: baotrandole@g.ucla.edu; 0000-0003-3233-6965
- 3 Sedighe Karimzadeh: sediqekarimzadeh@gmail.com; 0000-0002-9981-4404
- 4 Parshal Bhandari: parshalbhandari@gmail.com; ORCID: 0000-0001-8311-8466
- 5 Jaffer Shah: jaffer.shah@drexel.edu; 0000-0002-8961-218X
- 6 Jeza Muhamad Abdul Aziz: jeza1981@gmail.com; 0000-0002-1522-1880
- 7 Nguyen Tien Huy: tienhuy@nagasaki-u.ac.jp; 0000-0002-9543-9440

1 **ABSTRACT**

2 **Objective**

3 Coronavirus disease 2019 (COVID-19) has caused high morbidity and mortality worldwide. Since
4 there is not enough evidence of risk factors of SARS-CoV-2 transmission, this study aimed to
5 evaluate them.

6 **Methods**

7 This survey-based study was conducted across 66 countries from May to November 2020 among
8 suspected and confirmed individuals with COVID-19. The stepwise AIC method was utilized to
9 determine the optimal multivariable logistic regression to explore predictive factors of SARS-
10 CoV-2 transmission.

11 **Results**

12 Among 2372 respondents who participated in the study, there were 1172 valid responses. The
13 profession of non-healthcare-worker (OR: 1.77, 95%CI: 1.04 – 3.00, p=0.032), history of SARS-
14 CoV or MERS-CoV infection (OR: 4.78, 95%CI: 2.34 – 9.63, p<0.001), higher frequency of
15 contact with colleagues (OR: 1.17, 95%CI: 1.01 – 1.37, p=0.041), and habit of hugging when
16 greeting (OR: 1.25, 95%CI: 1.00 – 1.56, p=0.049) were associated with an increased risk of
17 contracting COVID-19. Current smokers had a lower likelihood of having COVID-19 compared
18 to former smokers (OR: 5.41, 95%CI: 1.93-17.49, p=0.002) or non-smokers (OR: 3.69, 95%CI:
19 1.48-11.11, p=0.01).

20 **Conclusions**

21 Our study suggests several risk factors for SARS-CoV-2 transmission including the profession of
22 non-healthcare workers, history of other coronavirus infections, frequent close contact with
23 colleagues, the habit of hugging when greeting, and smoking status.

24 **Keywords**

25 COVID-19, Global Survey, Health Surveys, Risk Factors, Transmission
26

27 **Plain Language Summary**

28 Since there is not enough evidence of risk factors of SARS-CoV-2 transmission, this study aimed
29 to evaluate them. The risk of SARS-CoV-2 infection was higher among non-healthcare workers
30 and among those who had a history of being tested positive for SARS-CoV or MERS-CoV before
31 the COVID-19 outbreak. The habit of frequent contact with colleagues or hugging when greeting

1 significantly increased the risk of being infected with SARS-CoV-2. The current smokers had a
2 lower risk of getting infected with SARS-CoV-2 than others who had a habit of smoking tobacco
3 in the past or who had never smoked.

1 INTRODUCTION

2 Coronavirus disease 2019 (COVID-19) is a contagious respiratory disease caused by severe
3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2).[1] Since December 2019, when initial
4 cases were identified in Wuhan, China, the disease has rapidly spread across 220 countries and
5 territories around the world and became a pandemic.[2] The ongoing pandemic has caused
6 significant morbidity and mortality with 585 950 085 confirmed cases and 6 425 422 deaths
7 worldwide as of August 12, 2022.[3] Therefore, there is an urgent need to control disease
8 transmission.

9 Human transmission of SARS-CoV-2 is primarily via respiratory droplets through a
10 mucosal or direct inhalation route.[4] While most coronaviruses are spread through respiratory
11 droplets, SARS-CoV-2 shows environmental resistance, making transmission possible through
12 surfaces, hands, air, water, and waste.[5] The aerosol transmission was reported to be another
13 possible route.[6] However, this notion is still controversial. Some of the common factors that
14 affect the transmission of this disease include non-compliance to public health protocols, attending
15 social gatherings, staying in poorly ventilated areas, deprivation and population density. [5,7].
16 Medical comorbidities such as chronic kidney disease, mental illness or cancer were shown to be
17 associated with an increased risk of SARS-CoV-2 infection.[8,9]

18 Despite various precautions (including border closures, social distancing, mask-wearing,
19 and handwashing practices) that have been implemented to prevent the spread of SARS-CoV-2,
20 there have been reports of several super-spreading events that led to many secondary infected cases
21 and in some similar situations led to a community transmission of SARS-CoV-2.[4,5,7,10] Super-
22 spreading may also be used to describe settings and events. Settings include cruise ships, airplanes,
23 hospitals, care homes, schools, workplaces, and hotels, while events involve large gatherings or
24 movements of groups or individuals.[11,12] These super-spreaders perhaps have some common
25 characteristics that can be the risk factors of rapid transmission.[10,11] Identifying these factors
26 will be very helpful in controlling disease transmission.

27 In the context of the ongoing COVID-19 pandemic, we conducted this study to evaluate
28 the risk factors of COVID-19 transmission. The results can help to better understand the
29 transmission dynamics of SARS-CoV-2 and potentially prevent and control the infection.

30 MATERIALS AND METHODS

31 Study design and participants

1 This multinational cross-sectional study aimed to detect the risk factors associated with
2 transmission of SARS-CoV-2 infection. The data collection lasted for 7 months from May to
3 November 2020 and reached 66 countries. The target population of this study was suspected and
4 confirmed individuals with SARS-CoV-2 infection divided into two groups: the F0 group
5 including individuals who were confirmed with SARS-CoV-2 infection; and the non-F0 group
6 including individuals who had close contact with F0, who were suspected to be infected with
7 SARS-CoV-2 during contact-tracing, who returned from affected geographic areas, or who lived,
8 stayed, or worked at a place nearby F0. Additional selection criteria of the target population
9 included individuals who were quarantined or isolated in hospitals or quarantine facilities. Those
10 who were quarantined at home due to lockdown measures were excluded from the study.

11 A convenience sampling method was employed in this study with no restriction on age,
12 gender, race, religion, marital status, education, and employment status. The recruitment of
13 respondents was done via social media accounts of the authors and collaborators by sharing and
14 posting the survey links. SurveyMonkey (SVMK Inc., San Mateo, CA, USA) was used as a
15 platform to create the questionnaire and collect the data. The web-based survey data was extracted
16 and encrypted for analysis ensuring confidentiality was maintained. All respondents filled out an
17 informed consent indicated on the first page of the survey. The study obtained academic and ethical
18 approval from the Institutional Review Board Office of the School of Tropical Medicine and
19 Global Health, Nagasaki University, Japan (Reference number: NU_TMGGH_2020_118_1).

20 **Survey questionnaire**

21 The survey was carried out using a structured questionnaire prepared by the authors based
22 on previous related studies, which included questions on demographic characteristics, disease-
23 related characteristics, environmental factors, behavioral factors, knowledge of disease prevention,
24 and past medical history.[13-16] The original English questionnaire was validated by a pilot survey
25 of 30 medical students and 10 subjects who were quarantined during the COVID-19 pandemic to
26 ensure the validity and reliability of the survey questions. The original questionnaire was then
27 translated into 15 languages (Albanian, Arabic, Filipino, German, Hindi, Indonesian, Korean,
28 Kurdish, Malayalam, Nepali, Russian, Spanish, Tamil, Ukrainian, and Urdu), to widen the reach
29 of respondents. Both forward and reverse translation for each language was performed. The
30 translated questionnaire in each language was pretested on five native speakers and modified if

1 needed. The original English survey questionnaire and the 15 translated versions were detailed in
2 Supplementary file S2.

3 **Statistical analysis**

4 The gathered data were organized and collected in an Excel spreadsheet (Microsoft Corp.,
5 Redmond, Washington, USA), which was then processed and analyzed using R language version
6 4.0.2. In the descriptive statistics section, we compare the difference between the F0 and non-F0
7 groups using the Student's T-test, Mann-Whitney U, Chi-square, and Phi and Cramer's V tests.
8 We treated 5-Likert scale responses as continuous variables and calculated the Odds ratios (ORs)
9 for each increase in frequency with values from 1 to 5 referring to the base factor level of 1
10 (never).[17] Multivariable logistic regression analysis using the Stepwise Akaike information
11 criterion (AIC) method on the MASS package was performed to explore the predictive factors of
12 SARS-CoV-2 transmission. The potential explanatory variables were selected through AIC
13 method to determine the optimal fit model in predicting the risk of getting SARS-CoV2.
14

15 **RESULTS**

16 **Characteristics of study participants**

17 Among 2372 respondents who participated in the study, there were a total of 1172 (49.4%)
18 valid responses. The median age of participants was 29 years (IQR 23-28.8). The male/female
19 ratio was 1/1.1. Healthcare workers composed 40.3% of the respondents. **Table 1** summarized the
20 sociodemographic characteristics of participants, divided into F0 and non-F0 groups. The F0 and
21 non-F0 groups were statistically different in their profession, race, religion, marital and
22 employment status, history of having a positive test for SARS-CoV or MERS-CoV before the
23 COVID-19 outbreak, medical history of high blood pressure, and history of getting influenza
24 vaccination in the past 12 months ($p < 0.05$).

25 **Table 1. Sociodemographic characteristics of F0 and non-F0 groups**

| | Non-F0 | F0 | Total | p-value |
|----------------------------|---------------------------|-------------------------|----------------------------|----------------|
| Age (Median – IQR) | 29 (23 – 38.5) (n=972) | 28 (23 – 39) (n=155) | 29 (23 – 38.8) (n=1127) | 0.884 |
| Gender (n=1116) | | | | 0.078 |
| Female | 518 (53.8) | 70 (45.8) | 588 (52.7) | |
| Male | 445 (46.2) | 83 (54.2) | 528 (47.3) | |
| Profession (n=1121) | | | | <0.001 |
| Healthcare worker | 365 (37.7) | 87 (56.5) | 452 (40.3) | |
| Non-healthcare worker | 602 (62.3) | 67 (43.5) | 669 (59.7) | |
| Race (n=1121) | | | | 0.003 |

| | | | | |
|--|------------|-----------|------------|------------------|
| White / Caucasian | 310 (32.1) | 40 (25.8) | 350 (31.3) | |
| Asian | 418 (43.3) | 84 (54.2) | 502 (44.8) | |
| Hispanic / Latino | 74 (7.6) | 18 (11.6) | 92 (8.2) | |
| Others | 164 (17.0) | 13 (8.4) | 177 (15.7) | |
| Religion (n=1126) | | | | |
| No religion | 218 (22.4) | 14 (9.1) | 232 (20.6) | 0.005 |
| Buddhist | 37 (3.8) | 5 (3.2) | 42 (3.7) | |
| Christian | 272 (28.0) | 48 (31.2) | 320 (28.4) | |
| Hindu | 84 (8.7) | 15 (9.7) | 99 (8.8) | |
| Muslim | 329 (33.8) | 68 (44.2) | 397 (35.3) | |
| Others | 32 (3.3) | 4 (2.6) | 36 (3.2) | |
| Marital status (n=1066) | | | | |
| Single | 476 (52.0) | 66 (43.7) | 542 (50.9) | 0.029 |
| Divorced/ Widowed/ Separated | 41 (4.5) | 3 (2.0) | 44 (4.1) | |
| Married/ Domestic partnership | 398 (43.5) | 82 (54.3) | 480 (45.0) | |
| Education (n=1126) | | | | |
| Master/ PhD/ Doctoral | 81 (8.3) | 10 (6.5) | 91 (8.1) | 0.094 |
| Undergraduate level | 219 (22.6) | 49 (31.6) | 268 (23.8) | |
| Primary school/ Secondary school/ High school | 270 (27.8) | 46 (29.7) | 316 (28.1) | |
| Vocational training | 365 (37.6) | 45 (29.0) | 410 (36.4) | |
| No formal education | 10 (1.0) | 0 (0.0) | 10 (0.9) | |
| Others | 26 (2.7) | 5 (3.2) | 31 (2.8) | |
| Employment status (n=1126) | | | | |
| Full-time employment | 322 (33.2) | 69 (44.5) | 391 (34.7) | 0.043 |
| Casual employment | 67 (6.9) | 8 (5.2) | 75 (6.7) | |
| Others | 22 (2.2) | 3 (1.94) | 25 (2.2) | |
| Part-time employment | 171 (17.6) | 27 (17.4) | 198 (17.6) | |
| Retired | 27 (2.8) | 6 (3.9) | 33 (2.9) | |
| Student | 260 (26.8) | 23 (14.8) | 283 (25.1) | |
| Unemployed | 102 (10.5) | 19 (12.3) | 121 (10.7) | |
| History of a positive test for SARS-CoV or MERS-CoV before COVID-19 outbreak (n=1073) | 48 (5.2) | 25 (16.9) | 73 (6.8) | <0.001 |
| Past medical history | | | | |
| Diabetes mellitus | 40 (4.4) | 10 (7.0) | 50 (4.8) | 0.251 |
| Hypertension | 53 (5.9) | 17 (12.0) | 70 (6.7) | 0.011 |
| Ischemic heart disease | 12 (1.3) | 3 (2.1) | 15 (1.4) | 0.444 |
| Heart failure | 14 (1.6) | 3 (2.1) | 17 (1.6) | 0.494 |
| Renal impairment | 9 (1.0) | 3 (2.1) | 12 (1.1) | 0.216 |
| HIV infection | 6 (0.7) | 1 (0.7) | 7 (0.7) | 1.000 |
| COPD | 3 (0.3) | 0 (0.0) | 3 (0.3) | 1.000 |
| History of allergy (n=1073) | 321 (34.7) | 60 (40.5) | 381 (35.5) | 0.195 |
| Allergic rhinitis | 174 (42.3) | 41 (53.2) | 215 (44.1) | 0.100 |
| Asthma | 89 (21.7) | 17 (22.1) | 106 (21.7) | 1.000 |
| Eczema | 43 (10.5) | 10 (13.0) | 53 (10.9) | 0.650 |
| Drug allergy | 42 (10.2) | 14 (18.2) | 56 (11.5) | 0.069 |
| Food allergy | 105 (25.5) | 17 (22.1) | 122 (25.0) | 0.616 |
| Current tobacco smoking status (n=801) | | | | |
| Current tobacco smoking | 112 (16.0) | 10 (9.8) | 122 (15.2) | 0.103 |
| Former tobacco smoking | 106 (15.2) | 22 (21.6) | 128 (16.0) | |
| Never smoking | 481 (68.8) | 70 (68.6) | 551 (68.8) | |
| History of getting influenza vaccination in the past 12 months (n=897) | | | | |
| | | | | 0.004 |

| | | | | |
|---|------------|-----------|------------|-------|
| Yes | 195 (25.0) | 46 (39.3) | 241 (26.9) | 0.645 |
| No | 512 (65.6) | 60 (51.3) | 572 (63.8) | |
| I do not remember | 73 (9.4) | 11 (9.4) | 84 (9.4) | |
| History of getting BCG vaccination in childhood (n=1070) | | | | |
| Yes | 409 (44.4) | 66 (44.6) | 475 (44.4) | |
| No | 161 (17.5) | 30 (20.3) | 191 (17.9) | |
| I do not remember | 352 (38.1) | 52 (35.1) | 404 (37.7) | |

1 Numbers in the parentheses indicate percentage (%), unless indicated otherwise. BCG: Bacille
2 Calmette-Guerin; COPD: chronic obstructive pulmonary disease; COVID-19: Coronavirus
3 Disease 2019; HIV: human immunodeficiency virus; IQR: Inter-quartile range; MERS-CoV:
4 Middle East respiratory syndrome coronavirus; NS: not significant; SARS-CoV: Severe acute
5 respiratory syndrome coronavirus; SD: standard deviation.

7 **The habit of wearing a face mask**

8 **Table 2** summarized the explored characteristics of the habit of wearing face masks among
9 participants during two weeks before the quarantine or isolation period. Generally, F0 and non-F0
10 groups were not statistically different in their habit of wearing face masks, including the frequency
11 of wearing face masks and the type of face mask. However, a higher proportion of respondents in
12 the F0 group had the habit of wearing facemasks at the workplace compared to the non-F0 group
13 (47.7% vs. 38.8%) (p=0.046).

14 **Table 2. The habit of wearing face masks during two weeks before the quarantine/ isolation**
15 **period**

| | Non-F0 | F0 | Total | p-value |
|---|------------|-----------|------------|--------------|
| Frequency of wearing a face mask during 2 weeks before quarantine/isolation (n=1066) | | | | |
| Never | 125 (13.7) | 13 (8.50) | 138 (12.9) | 0.283 |
| Rarely | 68 (7.45) | 13 (8.50) | 81 (7.6) | |
| Sometimes | 144 (15.8) | 32 (20.9) | 176 (16.5) | |
| Usually | 204 (22.3) | 34 (22.2) | 238 (22.3) | |
| Always | 372 (40.7) | 61 (39.9) | 433 (40.6) | |
| Wear a face mask at home | 113 (12.1) | 25 (16.3) | 138 (12.7) | 0.185 |
| Wear a face mask at workplace | 362 (38.8) | 73 (47.7) | 435 (40.1) | 0.046 |
| Wear a face mask in public places | 531 (56.9) | 91 (59.5) | 622 (57.3) | 0.613 |
| Wear a face mask whenever I go outside | 474 (50.8) | 91 (59.5) | 565 (52.0) | 0.057 |
| Using cloth face mask | 336 (35.9) | 53 (34.4) | 389 (35.7) | 0.791 |
| Using surgical face mask | 544 (58.1) | 92 (59.7) | 636 (58.3) | 0.772 |
| Using N95 respirator mask | 164 (17.5) | 36 (23.4) | 200 (18.3) | 0.104 |

16 Numbers in the parentheses indicate percentage (%), unless indicated otherwise. NS: not
17 significant.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Environmental and behavioral factors

The environmental and behavioral factors between F0 and non-F0 groups were compared and summarized in **Table 3**. A higher proportion of respondents in the F0 group used a car to go to work/school compared to the non-F0 group (67.3% vs. 54.8%, p=0.005), while more subjects in the latter group had a habit of going to work/school on foot (26.9% vs. 18.7%, p=0.042). Compared to the non-F0 group, the F0 group reported more frequently being in close contact with colleagues as well as paying a visit to crowded places (p=0.025 and p=0.002, respectively). Regarding the hand-washing habit, the F0 group had a lower frequency of hand washing before or after caring for someone at home, who was sick with vomiting or diarrhea (p=0.022), or after touching animals or animal-related wastes (p=0.041) compared to the non-F0 group. Also, there was a higher proportion of subjects in the F0 group reported only cleaning their hands with hand sanitizer compared to the non-F0 group (29.7% vs. 20.8%, p=0.019).

Table 3. Comparison of the environmental and behavior factors between F0 and non-F0 groups

| | Non-F0 | F0 | Total | p-value |
|--|------------|-----------|------------|---------|
| How often did you use an air conditioner at home? (n=827) | | | | |
| Never | 280 (40.1) | 50 (38.8) | 330 (39.9) | 0.991 |
| Rarely | 63 (9.1) | 12 (9.2) | 75 (9.1) | |
| Sometimes | 98 (14.0) | 18 (14.0) | 116 (14.0) | |
| Usually | 149 (21.3) | 30 (23.3) | 179 (21.6) | |
| Always | 108 (15.5) | 19 (14.7) | 127 (15.4) | |
| How often were you involved in a family gathering? (n=1108) | | | | |
| Never | 241 (25.1) | 31 (20.4) | 272 (24.5) | 0.722 |
| Rarely | 252 (26.4) | 45 (29.6) | 297 (26.8) | |
| Sometimes | 253 (26.5) | 41 (27.0) | 294 (26.5) | |
| Usually | 129 (13.5) | 23 (15.1) | 152 (13.7) | |
| Always | 81 (8.5) | 12 (7.9) | 93 (8.5) | |
| How often did you have contact with your pet or other animals in your house? (n=1106) | | | | |
| Never | 526 (55.0) | 78 (52.3) | 604 (54.6) | 0.755 |
| Rarely | 90 (9.4) | 13 (8.7) | 103 (9.3) | |
| Sometimes | 71 (7.4) | 14 (9.4) | 85 (7.7) | |
| Usually | 79 (8.3) | 16 (10.8) | 95 (8.6) | |
| Always | 191 (19.9) | 28 (18.8) | 219 (19.8) | |

| | | | | |
|---|------------|------------|------------|--------------|
| Using car to go to work/school | 526 (54.8) | 101 (67.3) | 627 (56.5) | 0.005 |
| Using train to go to work/school | 46 (4.8) | 6 (4.0) | 52 (4.7) | 0.827 |
| Using motorbike to go to work/school | 117 (12.2) | 19 (12.7) | 136 (12.3) | 0.974 |
| Using taxi to go to work/school | 90 (9.4) | 18 (12.0) | 108 (9.7) | 0.389 |
| Using bicycle to go to work/school | 52 (5.4) | 9 (6.0) | 61 (5.5) | 0.921 |
| Using metro-train to go to work/school | 41 (4.3) | 8 (5.3) | 49 (4.4) | 0.707 |
| Using bus to go to work/school | 177 (18.4) | 24 (16.0) | 201 (18.1) | 0.544 |
| Using walking to go to work/school | 258 (26.9) | 28 (18.7) | 286 (25.8) | 0.042 |
| At your workplace, did you work in a private room or a shared working room? (n=1138) | | | | 0.358 |
| Working in a private room | 211 (34.3) | 35 (29.4) | 246 (21.6) | |
| Working in a shared working room | 405 (65.7) | 84 (70.6) | 489 (43.0) | |
| Using air conditioner at work | 341 (53.0) | 62 (50.0) | 403 (35.4) | 0.614 |
| How often did you attend your workplace? (n=1039) | | | | 0.236 |
| Intermittent attendance | 229 (25.5) | 34 (24.3) | 263 (24.1) | |
| No attendance | 252 (28.0) | 31 (22.1) | 283 (25.9) | |
| Regular attendance | 418 (46.5) | 75 (53.6) | 493 (45.1) | |
| How often did you have close contact with your colleagues? (n=1064) | | | | 0.025 |
| Never | 173 (18.8) | 28 (19.3) | 201 (18.9) | |
| Rarely | 211 (23.0) | 23 (15.9) | 234 (22.0) | |
| Sometimes | 251 (27.3) | 47 (32.4) | 298 (28.0) | |
| Usually | 189 (20.6) | 22 (15.2) | 211 (19.8) | |
| Always | 95 (10.3) | 25 (17.2) | 120 (11.3) | |
| How often did you go to crowded places where you were in close contact with one another (within about 2 meters) (n=1102) | | | | 0.002 |
| Never | 188 (19.7) | 20 (13.3) | 208 (18.9) | |
| Rarely | 325 (34.1) | 50 (33.3) | 375 (34.0) | |
| Sometimes | 281 (29.5) | 50 (33.3) | 331 (30.0) | |
| Usually | 129 (13.6) | 16 (10.7) | 145 (13.2) | |
| Always | 29 (3.05) | 14 (9.3) | 43 (3.9) | |
| When you coughed or sneezed, how often did you cover your mouth and nose? (n=1112) | | | | 0.930 |
| Never | 39 (4.1) | 7 (4.6) | 46 (4.1) | |
| Rarely | 41 (4.3) | 7 (4.6) | 48 (4.3) | |
| Sometimes | 82 (8.5) | 15 (9.9) | 97 (8.7) | |
| Usually | 230 (23.9) | 32 (21.3) | 262 (23.6) | |
| Always | 569 (59.2) | 90 (59.6) | 659 (59.3) | |
| How did you usually cover your mouth when you were coughing or sneezing? (n=1111) | | | | 0.109 |
| Use towel or tissue paper | 199 (20.7) | 35 (23.2) | 234 (21.1) | |

| | | | | |
|---|------------|------------|------------|--------------|
| Use your elbow | 425 (44.3) | 53 (35.1) | 478 (43.0) | |
| Use your hand | 159 (16.6) | 24 (15.9) | 183 (16.5) | |
| Wear a face mask | 160 (16.7) | 37 (24.5) | 197 (17.7) | |
| Without any cover | 17 (1.77) | 2 (1.32) | 19 (1.7) | |
| Did you spit in public? (n=1115) | | | | |
| Never | 713 (74.0) | 111 (73.0) | 824 (73.9) | 0.263 |
| Rarely | 132 (13.7) | 22 (14.5) | 154 (13.8) | |
| Sometimes | 96 (10.0) | 12 (7.9) | 108 (9.7) | |
| Usually | 17 (1.8) | 4 (2.6) | 21 (1.9) | |
| Always | 5 (0.5) | 3 (2.0) | 8 (0.7) | |
| Did you shake hands when greeting? (n=1118) | | | | |
| Never | 411 (42.5) | 63 (41.4) | 474 (42.4) | 0.337 |
| Rarely | 237 (24.5) | 40 (26.3) | 277 (24.8) | |
| Sometimes | 199 (20.6) | 23 (15.1) | 222 (19.9) | |
| Usually | 89 (9.2) | 19 (12.5) | 108 (9.7) | |
| Always | 30 (3.1) | 7 (4.6) | 37 (3.3) | |
| Did you hug when greeting? (n=1117) | | | | |
| Never | 473 (49.0) | 68 (44.7) | 541 (48.4) | 0.119 |
| Rarely | 247 (25.6) | 39 (25.7) | 286 (25.6) | |
| Sometimes | 166 (17.2) | 23 (15.1) | 189 (16.9) | |
| Usually | 61 (6.3) | 19 (12.5) | 80 (7.2) | |
| Always | 18 (1.9) | 3 (1.97) | 21 (1.9) | |
| Wash your hands - Before, during, and after preparing food (n=1111) | | | | |
| Never | 11 (1.2) | 4 (2.6) | 15 (1.4) | 0.190 |
| Rarely | 26 (2.7) | 5 (3.3) | 31 (2.8) | |
| Sometimes | 55 (5.7) | 14 (9.3) | 69 (6.2) | |
| Usually | 240 (25.0) | 33 (21.9) | 273 (24.6) | |
| Always | 628 (65.4) | 95 (62.9) | 723 (65.1) | |
| Wash your hands - Before eating food (n=1106) | | | | |
| Never | 16 (1.7) | 1 (0.7) | 17 (1.5) | 0.676 |
| Rarely | 33 (3.5) | 7 (4.6) | 40 (3.6) | |
| Sometimes | 92 (9.6) | 13 (8.6) | 105 (9.5) | |
| Usually | 199 (20.8) | 37 (24.5) | 236 (21.3) | |
| Always | 615 (64.4) | 93 (61.6) | 708 (64.0) | |
| Wash your hands - Before and after caring for someone at home who is sick with vomiting or diarrhea (n=1057) | | | | 0.022 |
| Never | 39 (4.3) | 6 (4.2) | 45 (4.3) | |

| | | | | |
|--|------------|------------|------------|-------|
| Rarely | 18 (2.0) | 10 (6.9) | 28 (2.6) | |
| Sometimes | 37 (4.0) | 7 (4.9) | 44 (4.2) | |
| Usually | 118 (12.9) | 13 (9.0) | 131 (12.4) | |
| Always | 701 (76.8) | 108 (75.0) | 809 (76.5) | |
| Wash your hands - Before and after treating a cut or wound (n=1066) | | | | |
| Never | 28 (3.1) | 4 (2.7) | 32 (3.0) | 0.966 |
| Rarely | 22 (2.4) | 4 (2.7) | 26 (2.4) | |
| Sometimes | 60 (6.5) | 10 (6.9) | 70 (6.6) | |
| Usually | 131 (14.2) | 23 (15.8) | 154 (14.4) | |
| Always | 679 (73.8) | 105 (71.9) | 784 (73.6) | |
| Wash your hands - After using the toilet (n=1099) | | | | |
| Never | 9 (0.9) | 2 (1.3) | 11 (1.0) | 0.223 |
| Rarely | 18 (1.9) | 5 (3.4) | 23 (2.1) | |
| Sometimes | 36 (3.8) | 3 (2.0) | 39 (3.5) | |
| Usually | 112 (11.8) | 11 (7.4) | 123 (11.2) | |
| Always | 775 (81.6) | 128 (85.9) | 903 (82.2) | |
| Wash your hands - After changing diapers or cleaning up a child who has used the toilet (n=986) | | | | |
| Never | 39 (4.5) | 8 (6.2) | 47 (4.8) | 0.809 |
| Rarely | 20 (2.3) | 4 (3.1) | 24 (2.4) | |
| Sometimes | 35 (4.1) | 6 (4.7) | 41 (4.2) | |
| Usually | 94 (11.0) | 13 (10.1) | 107 (10.9) | |
| Always | 669 (78.1) | 98 (76.0) | 767 (77.8) | |
| Wash your hands - After blowing your nose, coughing, or sneezing (n=1095) | | | | |
| Never | 28 (2.9) | 5 (3.5) | 33 (3.0) | 0.841 |
| Rarely | 45 (4.7) | 8 (5.5) | 53 (4.8) | |
| Sometimes | 153 (16.1) | 25 (17.4) | 178 (16.3) | |
| Usually | 246 (25.9) | 40 (27.8) | 286 (26.1) | |
| Always | 479 (50.4) | 66 (45.8) | 545 (49.8) | |
| Wash your hands - After touching an animal, animal feed, or animal waste (n=1020) | | | | |
| Never | 39 (4.4) | 11 (8.1) | 50 (4.9) | 0.041 |
| Rarely | 27 (3.0) | 10 (7.4) | 37 (3.6) | |
| Sometimes | 97 (11.0) | 12 (8.9) | 109 (10.7) | |
| Usually | 137 (15.5) | 17 (12.6) | 154 (15.1) | |
| Always | 585 (66.1) | 85 (63.0) | 670 (65.7) | |
| Wash your hands - After handling pet food or pet treats (n=865) | | | | |
| Never | 60 (7.9) | 14 (13.2) | 74 (8.6) | 0.123 |

| | | | | |
|--|------------|------------|------------|--------------|
| Rarely | 52 (6.9) | 7 (6.6) | 59 (6.8) | |
| Sometimes | 80 (10.5) | 16 (15.1) | 96 (11.1) | |
| Usually | 143 (18.8) | 22 (20.8) | 165 (19.1) | |
| Always | 424 (55.9) | 47 (44.3) | 471 (54.5) | |
| Wash your hands - After touching garbage (n=1085) | | | | |
| Never | 15 (1.6) | 4 (2.8) | 19 (1.8) | 0.838 |
| Rarely | 24 (2.5) | 3 (2.1) | 27 (2.5) | |
| Sometimes | 63 (6.7) | 9 (6.4) | 72 (6.6) | |
| Usually | 130 (13.8) | 18 (12.8) | 148 (13.6) | |
| Always | 712 (75.4) | 107 (75.9) | 819 (75.5) | |
| Which of the following did you wash your hands with? | | | | |
| Running water only | 112 (11.6) | 18 (12.2) | 130 (11.7) | 0.960 |
| Running water and soap | 731 (75.9) | 114 (77.0) | 845 (76.1) | 0.847 |
| Running water + antibacterial liquid hand wash | 403 (41.8) | 61 (41.2) | 464 (48.1) | 0.956 |
| Hand sanitizer only | 200 (20.8) | 44 (29.7) | 244 (22.0) | 0.019 |
| Hand wipes | 68 (7.1) | 15 (10.1) | 83 (7.5) | 0.249 |
| How long did you usually wash your hands? (n=1116) | | | | |
| < 20 seconds | 401 (41.7) | 73 (47.4) | 474 (42.5) | 0.390 |
| 20 - 60 seconds | 479 (49.8) | 68 (44.2) | 547 (49.0) | |
| > 60 seconds | 82 (8.5) | 13 (8.4) | 95 (8.5) | |
| Generally, what was the distance between you and the person you talked with? (n=1116) | | | | |
| < 0.5 m | 175 (18.2) | 33 (21.6) | 208 (18.6) | 0.610 |
| 0.5 - 1 m | 368 (38.2) | 60 (39.2) | 428 (38.4) | |
| 1 - 2 m | 313 (32.5) | 47 (30.7) | 360 (32.2) | |
| > 2 m | 107 (11.1) | 13 (8.5) | 120 (10.8) | |
| How often did you clean “high-touch” surfaces? (n=1053) | | | | |
| Never | 69 (7.7) | 13 (8.5) | 82 (7.8) | 0.693 |
| Rarely | 129 (14.3) | 24 (15.7) | 153 (14.5) | |
| Sometimes | 289 (32.1) | 53 (34.6) | 342 (32.5) | |
| Usually | 253 (28.1) | 43 (28.1) | 296 (28.1) | |
| Always | 160 (17.8) | 20 (13.1) | 180 (17.1) | |
| How often did you share personal household items with others? (n=1111) | | | | |
| Never | 266 (27.8) | 39 (25.2) | 305 (27.5) | 0.902 |
| Rarely | 266 (27.8) | 47 (30.3) | 313 (28.2) | |
| Sometimes | 229 (24.0) | 40 (25.8) | 269 (24.2) | |
| Usually | 131 (13.7) | 20 (12.9) | 151 (13.6) | |

| | | | | |
|---|------------|------------|------------|-------|
| Always | 64 (6.7) | 9 (5.8) | 73 (6.5) | |
| Did you often eat from hand-washed dishes or machine-washed ones? (n=1103) | | | | 0.972 |
| I often ate from hand-washed dishes | 757 (79.9) | 123 (79.4) | 880 (79.8) | |
| I often ate from machine-washed dishes | 191 (20.1) | 32 (20.6) | 223 (20.2) | |

Numbers in the parentheses indicate percentage (%), unless indicated otherwise.

Knowledge related to preventing the spread of disease to others

Table 4 summarizes and compares the knowledge related to preventing the spread of disease to others between F0 and non-F0 groups. All the explored knowledge characteristics were similar between F0 and non-F0 groups, except the knowledge of covering the nose and mouth when coughing or sneezing, and of sharing personal household items. Compared to the F0 group, there was a higher proportion of subjects in the non-F0 group who were aware that covering the nose and mouth when coughing or sneezing could help to prevent the disease transmission to others (80.6% vs. 71.8%, $p=0.028$). Also, more subjects in the non-F0 group were aware that avoiding sharing personal household items could prevent the spread of airborne infectious diseases compared to the F0 group (71.7% vs. 62.2%, $p=0.031$).

Table 4. Comparison of knowledge related to preventing the spread of disease to others between F0 and non-F0 groups

| Which of the following did you think you should do to prevent the spread of airborne infection disease to people around? | Non-F0 | F0 | Total | p- value |
|--|------------|------------|------------|----------|
| - Do not go to public places (n=1088) | | | | 0.804 |
| Yes | 679 (72.4) | 105 (70.0) | 784 (72.1) | |
| No | 228 (24.3) | 39 (26.0) | 267 (24.5) | |
| I do not know | 31 (3.30) | 6 (4.00) | 37 (3.4) | |
| - Do not use public transportation (n=1079) | | | | 0.534 |
| Yes | 643 (69.1) | 101 (68.2) | 744 (69.0) | |
| No | 225 (24.2) | 40 (27.0) | 265 (24.6) | |
| I do not know | 63 (6.77) | 7 (4.73) | 70 (6.5) | |
| - Stay away from others as much as possible (n=1080) | | | | 0.422 |
| Yes | 708 (75.9) | 105 (71.4) | 813 (75.3) | |

| | | | | |
|---|------------|------------|------------|-------|
| No | 195 (20.9) | 35 (23.8) | 230 (21.3) | |
| I do not know | 30 (3.22) | 7 (4.76) | 37 (3.4) | |
| - Use a separate bathroom if available (n=1082) | | | | |
| Yes | 659 (70.6) | 100 (67.1) | 759 (70.1) | 0.624 |
| No | 198 (21.2) | 34 (22.8) | 232 (21.4) | |
| I do not know | 76 (8.15) | 15 (10.1) | 91 (8.4) | |
| - Limit contact with pets and other animals or wash your hands before and after handling pets (n=1074) | | | | |
| Yes | 569 (61.4) | 85 (57.8) | 654 (60.9) | 0.406 |
| No | 265 (28.6) | 42 (28.6) | 307 (28.6) | |
| I do not know | 93 (10.0) | 20 (13.6) | 113 (10.5) | |
| - Wear a facemask when you are around other people (n=1082) | | | | |
| Yes | 701 (75.2) | 103 (68.7) | 804 (74.3) | 0.192 |
| No | 206 (22.1) | 41 (27.3) | 247 (22.8) | |
| I do not know | 25 (2.68) | 6 (4.00) | 31 (2.9) | |
| - Cover your nose and mouth when coughing or sneezing (n=1079) | | | | |
| Yes | 750 (80.6) | 107 (71.8) | 857 (79.4) | 0.028 |
| No | 164 (17.6) | 37 (24.8) | 201 (18.6) | |
| I do not know | 16 (1.72) | 5 (3.36) | 21 (1.9) | |
| - Wash your hands often (n=1075) | | | | |
| Yes | 738 (79.6) | 110 (74.3) | 848 (78.9) | 0.264 |
| No | 172 (18.6) | 36 (24.3) | 208 (19.3) | |
| I do not know | 17 (1.8) | 2 (1.4) | 19 (1.8) | |
| - Avoid sharing personal household items (n=1074) | | | | |
| Yes | 664 (71.7) | 92 (62.2) | 756 (70.4) | 0.031 |
| No | 203 (21.9) | 47 (31.8) | 250 (23.3) | |
| I do not know | 59 (6.4) | 9 (6.0) | 68 (6.3) | |
| - Clean all "high-touch" surfaces (n=1081) | | | | |
| Yes | 694 (74.5) | 100 (67.1) | 794 (73.5) | 0.159 |

| | | | |
|---------------|------------|-----------|------------|
| No | 194 (20.8) | 39 (26.2) | 233 (21.6) |
| I do not know | 44 (4.7) | 10 (6.7) | 54 (5.0) |

1 Numbers in the parentheses indicate percentage (%), unless indicated otherwise. NS: not
2 significant.

3

4 **Risk factors associated with SARS-CoV-2 transmission in multivariable logistic regression**

5 After performing the multivariable logistic regression analysis, we found that the
6 profession of non-healthcare-worker (OR: 1.77, 95% CI: 1.04 – 3.00, p=0.032), history of being
7 tested positive for SARS-CoV or MERS-CoV before the COVID-19 outbreak (OR: 4.78, 95% CI:
8 2.34 – 9.63, p<0.001), higher frequency of being in contact with colleagues (OR: 1.17, 95% CI:
9 1.01 – 1.37, p= 0.041), and habit of hugging when greeting (OR: 1.25, 95% CI: 1.00 – 1.56,
10 p=0.049) significantly increased the odds of being infected with SARS-CoV-2. Participants who
11 were suffering from diabetes mellitus were at higher risk of contracting SARS-CoV-2 but this
12 finding only approached the borderline of significance (OR: 2.54; 95% CI: 0.92 – 6.34, p=0.055).
13 Participants who were smoking tobacco currently had a lower likelihood of having COVID-19
14 compared to those who smoked previously (OR: 5.41, 95% CI: 1.93-17.49, p=0.002) or who never
15 smoked (OR: 3.69, 95% CI: 1.48-11.11, p=0.01) (**Table 5**).

16 **Table 5. Summary of multivariable logistic regression analysis for F0 cases**

| Predictors | Univariable | | | Multivariable | | |
|--|------------------|-------------|------------------|------------------|-------------|------------------|
| | OR | 95% CI | p-value | OR | 95% CI | p-value |
| Profession | | | | | | |
| Healthcare worker | <i>Reference</i> | | | <i>Reference</i> | | |
| Non-healthcare worker | 2.04 | 1.24 – 3.33 | 0.005 | 1.77 | 1.04 – 3.00 | 0.032 |
| Diabetes mellitus | | | | | | |
| No | <i>Reference</i> | | | <i>Reference</i> | | |
| Yes | 2.39 | 0.91 – 5.54 | 0.055 | 2.54 | 0.92 – 6.34 | 0.055 |
| Have you ever been tested positive for a coronavirus (SARS-CoV or MERS-CoV) before the COVID-19 outbreak? | | | | | | |
| No | <i>Reference</i> | | | <i>Reference</i> | | |
| Yes | 4.48 | 2.35 – 8.35 | <0.001 | 4.78 | 2.34 – 9.63 | <0.001 |

| | | | | | | |
|---|------------------|--------------|--------------|------------------|--------------|--------------|
| How often did you have close contact with your colleagues? ^a | 1.16 | 1.01 – 1.34 | 0.035 | 1.17 | 1.01 – 1.37 | 0.041 |
| Did you hug when greeting? ^a | 1.29 | 1.05 – 1.59 | 0.016 | 1.25 | 1.00 – 1.56 | 0.049 |
| Which of the following is your current tobacco smoking status? | | | | | | |
| Current tobacco smoking | <i>Reference</i> | | | <i>Reference</i> | | |
| Former tobacco smoking | 3.55 | 1.41 – 10.21 | 0.011 | 5.41 | 1.93 – 17.49 | 0.002 |
| Never smoking | 2.09 | 0.94 – 5.57 | 0.099 | 3.69 | 1.48 – 11.11 | 0.010 |
| Observations | | | | 607 | | |
| R ² Tjur | | | | 0.093 | | |

1 ^aThe frequency of close contact with colleagues and hugging when greeting with 5 specific levels
2 (1=never, 2=rarely, 3=sometimes, 4=usually, 5=always). COVID-19: Coronavirus Disease 2019;
3 MERS-CoV: Middle East respiratory syndrome coronavirus; NS: not significant; SARS-CoV:
4 Severe acute respiratory syndrome coronavirus; OR: odd ratio; CI: confidence interval.

5

6 **DISCUSSION**

7 Our study examined the risk factors associated with the transmission of SARS-CoV-2. In
8 the current study, among those who were confirmed or suspected to be infected with SARS-CoV-
9 2, non-healthcare workers were more likely to be infected with SARS-CoV-2 compared to
10 healthcare workers. Although healthcare workers were at the frontline in the combat against the
11 COVID-19 pandemic, our study showed that their risk of contracting SARS-CoV-2 infection may
12 be lower than the general population when in close contact with an infected person. This may be
13 attributed to the better awareness and preparedness of healthcare workers against COVID-19
14 compared to the general community.[18,19]

15 We found that participants with a history of SARS or MERS infection before the COVID-
16 19 outbreak significantly had increased odds of being infected with SARS-CoV-2 too. To date,
17 there are no adequate studies evaluating the immunity against COVID-19 following a prior
18 coronavirus infection. Previous studies indicated that antibody responses to coronavirus were
19 transient and waned rapidly after infection, contributing to the risk of reinfection.[20,21] The study
20 of Anderson *et al.* also reported that antibodies against seasonal human coronavirus were boosted
21 upon SARS-CoV-2 infection but were not associated with protection against this infection.[22]
22 Another possible mechanism is the antibody-dependent enhancement (ADE) occurrence, similar

1 to dengue infections when a second infection is caused by a different virus strain.[23] Longitudinal
2 studies are required to evaluate the relationship between the risk of SARS-CoV-2 infection and
3 the history of other coronavirus infections.

4 Previous studies reported that if there was an infected individual within the area of 400 m²,
5 their contact would imply a high risk for disease spreading, thus, reducing crowds in public spaces
6 might help in deducting the infection rate.[24,25] We also have a similar observation. Those who
7 were more frequently in close contact with one another (within 2 meters) had a higher possibility
8 of being infected with SARS-CoV-2. In line with this, those who had a habit of hugging when
9 greeting had a higher risk of having COVID-19.

10 The current study showed that current smokers had a lower possibility of getting infected
11 with SARS-CoV-2 than others who had a habit of smoking tobacco in the past or who had never
12 smoked. This accords with a previous study reporting that current smokers had a lower risk of
13 contracting COVID-19 compared to former smokers and non-smokers (OR, 0.64, 95%CI: 0.49-
14 0.84, $p < 0.001$).[26] On the contrary, several previous studies reported the negative impact of
15 smoking on COVID-19 progression and prognosis.[27-29] This discrepancy may be explained by
16 the inadequate quality of collected data on smoking status. “Former smokers” and “non-smokers”
17 may be misclassified as those who quit smoking a long time ago. Also, patients with COVID-19
18 may have quit smoking after having respiratory symptoms or before admission, thus, were not
19 recorded as “current smokers”. A meta-analysis of related papers using reliable self-report
20 measures of smoking status showed that current smokers were at reduced risk of contracting
21 COVID-19 compared to never smokers (RR = 0.74, 95% CI = 0.24-0.64).[30] This meta-analysis
22 also pointed out that there was no significant difference in hospitalization and disease severity of
23 COVID-19 between current and never smokers. However, compared to never smokers, former
24 smokers were at increased risk of hospitalization due to COVID-19 (RR = 1.20, 95% CI = 0.06-
25 0.37) and of greater disease severity (RR = 1.52, 95% CI = 0.47- 0.66).[30] The angiotensin-
26 converting enzyme 2 (ACE2) receptor has been confirmed to be the main entry of the SARS-CoV-
27 2 to the host mucosa and an increase in the risk of SARS-CoV-2 infection has been observed in
28 those receiving angiotensin-converting enzyme inhibitors.[31] To date, experimental models
29 reported conflicting results regarding the ACE2 expression in the lung epithelium of smokers. The
30 ACE2 expression in respiratory mucosa epithelia of smokers was shown to be downregulated
31 compared with non-smokers, which may explain the lower proportion of smokers in COVID-19

1 patients.[32] On the contrary, the study of Liu et al using a mouse model observed increased ACE2
2 levels in the bronchial epithelium but decreased ACE2 levels in the alveolar epithelium upon
3 smoke exposure.[33] The controversial findings of the association between smoking and COVID-
4 19 should be solved by further independent studies.

5 Diabetes was reported to be a major risk factor contributing to severity and mortality in
6 COVID-19 patients but did not increase the risk of COVID-19.[34] However, diabetes was
7 shown to be more common in patients with severe COVID-19.[34] In the present study, diabetes
8 status was self-reported by the participants through the survey questions. Participant self-report of
9 a diagnosis of diabetes has been validated to be a reliable method to evaluate diabetes status in
10 previous studies.[35,36] Although participants with diabetes had higher odds of getting infected
11 with SARS-CoV-2 but this finding only approached the borderline of significance ($p=0.055$). The
12 non-association between diabetes and the risk of getting COVID-19 may be due to the under-
13 reported rate of diabetes among the patients with COVID-19 or due to the analysis not considering
14 the severity of diabetes.

15 Results from our current findings may have some implications for policymakers in offering
16 preventive measures for COVID-19 such as health information dissemination to enhance the
17 awareness of COVID-19 among the community and physical distancing during the pandemic.
18 Although the current study showed that smoking was protective against SARS-CoV-2 infection,
19 smoking was reported to be associated with worse outcomes among COVID-19 patients.[27,29]
20 As a result, recommendation of smoking cessation should be maintained during the COVID-19
21 pandemic.

22 The current study had several limitations. Firstly, as it was a cross-sectional survey-based
23 study, our results only suggested possible associations between risk factors and COVID-19 but did
24 not determine the exact risk factors of getting COVID-19. Secondly, although our study covered
25 a large population from various geographical locations (66 countries), which ultimately
26 strengthened the study results and made it a global study, the limited number of participants who
27 were confirmed to have COVID-19 compared to non-infected participants might have partially
28 affected the results. Further studies are needed to evaluate the risk factors of SARS-CoV-2
29 transmission during the ongoing second wave of the pandemic.

30 **CONCLUSIONS**

1 Our study findings obtained from a wide geographic population suggest several possible
2 risk factors of SARS-CoV-2 transmission including the profession of non-healthcare worker,
3 history of other coronavirus infection, frequent close contact with colleagues, habit of hugging
4 when greeting, and tobacco smoking status. These observations required further investigations to
5 offer preventive measures for COVID-19.

6 7 **AUTHORS' STATEMENT**

8 **Authors' contributions:** NTH, MNL, STMA, NTMD, and LVT conceived the study and designed
9 the study protocol. MNL, STMA, NTMD, and LVT performed the data curation, software, formal
10 analysis, validation, and drafted the manuscript. AQ, VU, RT, ICNR, LHNM, RR, SPD, HTNG,
11 DP, FYA, BTDT, SK, PB, JS, JMAA, and the TMGH COVID-19 Collaborators carried out the
12 data investigation and critically revised the manuscript for intellectual content. All authors read
13 and approved the final manuscript. NTH supervised the study project.

14 **Acknowledgments:** none

15 **Funding:** This research did not receive any specific grant from funding agencies in the public,
16 commercial, or not-for-profit sectors.

17 **Competing interests:** none declared.

18 **Ethical approval:** The study obtained academic and ethical approval from the Institutional
19 Review Board Office of the School of Tropical Medicine and Global Health, Nagasaki University,
20 Japan (Reference number: NU_TMGH_2020_118_1).

21 **Data statement**

22 The data used to support the findings of this study are available from the corresponding author
23 upon request.

24 25 **REFERENCES**

- 26 1. World Health Organization. (2021). Naming the coronavirus disease (COVID-19) and the
27 virus that causes it. [cited 2021 June 7]. Available from:
28 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
29 [guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)

- 1 2. Worldometer. Countries where COVID-19 has spread. 2021 [cited 2021 18 April].
2 Available from: [https://www.worldometers.info/coronavirus/countries-where-
4 coronavirus-has-spread/](https://www.worldometers.info/coronavirus/countries-where-
3 coronavirus-has-spread/)
- 4 3. World Health Organization. (2022). WHO Coronavirus (COVID-19) Dashboard [cited
5 2022 August 12]. Available from: <https://covid19.who.int/>
- 6 4. World Health Organization. (2021). Modes of transmission of virus causing COVID-19:
7 implications for IPC precaution recommendations [cited 2021 June 7]. Available from:
8 [https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-
10 causing-covid-19-implications-for-ipc-precaution-recommendations](https://www.who.int/news-room/commentaries/detail/modes-of-transmission-of-virus-
9 causing-covid-19-implications-for-ipc-precaution-recommendations)
- 10 5. Vardoulakis S, Sheel M, Lal A, et al. COVID-19 environmental transmission and
11 preventive public health measures [<https://doi.org/10.1111/1753-6405.13033>]. Australian
12 and New Zealand Journal of Public Health. 2020 2020/10/01;44(5):333-335.
- 13 6. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-
14 CoV-2 as Compared with SARS-CoV-1. The New England journal of medicine. 2020 Apr
15 16;382(16):1564-1567.
- 16 7. Meghali NK, Chandrashekhar M, Melissa P, et al. COVID-19 pandemic: Social aspects
17 and safe behaviours. Journal of Critical Reviews. 2021;7(8):4.
- 18 8. De Vito A, Fiore V, Princic E, et al. Predictors of infection, symptoms development, and
19 mortality in people with SARS-CoV-2 living in retirement nursing homes. PloS one.
20 2021;16(3):e0248009.
- 21 9. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients
22 in the Oxford Royal College of General Practitioners Research and Surveillance Centre
23 primary care network: a cross-sectional study. The Lancet Infectious diseases. 2020
24 Sep;20(9):1034-1042.
- 25 10. Stein RA. Super-spreaders in infectious diseases. International journal of infectious
26 diseases : IJID : official publication of the International Society for Infectious Diseases.
27 2011 Aug;15(8):e510-3.
- 28 11. Cave E. COVID-19 Super-spreaders: Definitional Quandaries and Implications. Asian
29 Bioethics Review. 2020 2020/06/01;12(2):235-242.
- 30 12. Majra D, Benson J, Pitts J, et al. SARS-CoV-2 (COVID-19) superspreader events. J Infect.
31 2021;82(1):36-40.

- 1 13. CDC. (2020). When and How to Wash Your Hands. [cited 2020 March 25]. Available
2 from: <https://www.cdc.gov/handwashing/when-how-handwashing.html>
- 3 14. CDC. (2020). Steps to help prevent the spread of COVID-19 if you are sick. [cited 2020
4 March 20]. Available from: [https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-
5 sick/steps-when-sick.html](https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/steps-when-sick.html)
- 6 15. Eslami H, Jalili M. The role of environmental factors to transmission of SARS-CoV-2
7 (COVID-19). *AMB Express*. 2020 May 15;10(1):92.
- 8 16. Kutsuna S. Coronavirus disease 2019 (COVID-19): research progress and clinical practice.
9 *Global health & medicine*. 2020 Apr 30;2(2):78-88.
- 10 17. Norman G. Likert scales, levels of measurement and the "laws" of statistics. *Advances in
11 health sciences education : theory and practice*. 2010 Dec;15(5):625-32.
- 12 18. Mohsen F, Bakkar B, Armashi H, et al. Crisis within a crisis, COVID-19 knowledge and
13 awareness among the Syrian population: a cross-sectional study. *BMJ Open*.
14 2021;11(4):e043305.
- 15 19. Tripathi R, Alqahtani SS, Albarraq AA, et al. Awareness and Preparedness of COVID-19
16 Outbreak Among Healthcare Workers and Other Residents of South-West Saudi Arabia:
17 A Cross-Sectional Survey. *Frontiers in public health*. 2020;8:482-482.
- 18 20. Sariol A, Perlman S. Lessons for COVID-19 Immunity from Other Coronavirus Infections.
19 *Immunity*. 2020 Aug 18;53(2):248-263.
- 20 21. Zhao J, Alshukairi AN, Baharoon SA, et al. Recovery from the Middle East respiratory
21 syndrome is associated with antibody and T-cell responses. *Science immunology*. 2017
22 Aug 4;2(14).
- 23 22. Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are
24 boosted upon SARS-CoV-2 infection but not associated with protection. *Cell*.
25 2021;184(7):1858-1864.e10.
- 26 23. Ulrich H, Pillat MM, Tárnok A. Dengue Fever, COVID-19 (SARS-CoV-2), and Antibody-
27 Dependent Enhancement (ADE): A Perspective. *Cytometry Part A : the journal of the
28 International Society for Analytical Cytology*. 2020 Jul;97(7):662-667.
- 29 24. Güner R, Hasanoğlu I, Aktaş F. COVID-19: Prevention and control measures in
30 community. *Turk J Med Sci*. 2020;50(SI-1):571-577.

- 1 25. Sookaromdee P, Wiwanitkit V. Spreading of COVID-19 in a Common Place: Medical
2 Architecture Analysis. *International journal of preventive medicine*. 2020;11:52.
- 3 26. Paleiron N, Mayet A, Marbac V, et al. Impact of Tobacco Smoking on the risk of COVID-
4 19. A large scale retrospective cohort study. *Nicotine & tobacco research : official journal
5 of the Society for Research on Nicotine and Tobacco*. 2021 Jan 9.
- 6 27. Cattaruzza MS, Zagà V, Gallus S, et al. Tobacco smoking and COVID-19 pandemic: old
7 and new issues. A summary of the evidence from the scientific literature. *Acta bio-medica :
8 Atenei Parmensis*. 2020 May 11;91(2):106-112.
- 9 28. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in
10 hospitalized patients with 2019 novel coronavirus disease. *Chinese medical journal*. 2020
11 May 5;133(9):1032-1038.
- 12 29. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-
13 analysis. *Nicotine & tobacco research : official journal of the Society for Research on
14 Nicotine and Tobacco*. 2020 Aug 24;22(9):1653-1656.
- 15 30. Simons D, Shahab L, Brown J, et al. The association of smoking status with SARS-CoV-
16 2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review
17 with Bayesian meta-analyses (version 7) [10.1111/add.15276]. *Addiction*. 2021
18 2021/06/01;116(6):1319-1368.
- 19 31. De Vito A, Geremia N, Princic E, et al. Does Angiotensin II receptor blockers increase the
20 risk of SARS-CoV-2 infection? A real-life experience. *European review for medical and
21 pharmacological sciences*. 2021 Jan;25(1):523-526.
- 22 32. Li W, Zheng R, Liang R, et al. Effects of Smoking on ACE2 Expression Pattern: Risk and
23 Severity of SARS-CoV-2 Infection. *Clinical laboratory*. 2021 Jul 1;67(7).
- 24 33. Heijink IH, Hackett TL, Pouwels SD. Effects of cigarette smoking on SARS-CoV-2
25 receptor ACE2 expression in the respiratory epithelium(†). *The Journal of pathology*. 2021
26 Apr;253(4):351-354.
- 27 34. Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes:
28 understanding the reasons for worse outcomes. *The lancet Diabetes & endocrinology*. 2020
29 Sep;8(9):782-792.
- 30 35. Goto A, Morita A, Goto M, et al. Validity of diabetes self-reports in the Saku diabetes
31 study. *Journal of epidemiology*. 2013;23(4):295-300.

- 1 36. Moradpour F, Piri N, Dehghanbanadaki H, et al. Socio-demographic correlates of diabetes
2 self-reporting validity: a study on the adult Kurdish population. BMC Endocrine Disorders.
3 2022 2022/05/26;22(1):139.
4

1 **Table legends:**

2 Table 1. Sociodemographic characteristics of F0 and non-F0 groups

3 Table 2. The habit of wearing face masks during two weeks before the quarantine/ isolation period

4 Table 3. Comparison of knowledge related to preventing the spread of disease to others between
5 F0 and non-F0 groups

6 Table 4. Summary of multivariable logistic regression analysis for F0 cases

7 Supplementary table S3. Comparison of the environmental and behavior factors between F0 and
8 non-F0 groups